ETA2023 45th Annual Meeting of the European Thyroid Association ETA 2023 Oral Session 8: Hypothyrodism / Nodules (5 abstracts)
Individuals on levothyroxine have higher hads anxiety and depression scores than the general population and this is exacerbated by the THR92ALA substitution in DIO2, particularly at higher doses
Peter Taylor 1 , Eirin Haug 2 , Stephanie Hanna 3 , Adrian Heald 4 , Mike Stedman 5 , Lakdasa Premawardhana 6 , Onyebuchi Okosieme 7 , Bjørn Olav Æsvold 8 & Colin Dayan 9
1Cardiff University, School of Medicine, Cardiff University School of Medicine, Cardiff, United Kingdom; 2Ntnu; 3Cardiff University; 4Salford Royal Hospital, Endocrinology, Salford, United Kingdom; 5Res Consortium, United Kingdom; 6Yyf Hospital, University Hospital of Wales, Aneurin Bevan University Health Board, Cardiff, United Kingdom; 7Cardiff University, Prince Charles Hospital, Cardiff, United Kingdom; 8Hunt Research Centre, Øya, Norway; 9Thyroid Research Group, School of Medicine, Cardiff University, Cardiff, United Kingdom
Context: Approximately 15% of people with hypothyroidism remain symptomatic despite treatment. The Thr92Ala substitution in DIO2, may influence T3 tissue levels.
Methods: We assessed HADS anxiety and depression scores in HUNT2 in 50,901 individuals (6,687 homozygous for Thr92Ala) of whom 1,480 had a history of levothyroxine use (180 homozygous for Thr92Ala). Anxiety and depression caseness (score>=8) by levothyroxine and Thr92Ala status was assessed using logistic regression, adjusting for age, sex and educational attainment.
Results: The Thr92Ala substitution was present in 13% of the population and was not associated with increased HADS scores in individuals not on levothyroxine. Compared to individuals not on levothyroxine, HADS total score was 0.71 points higher (0.39-1.02, P < 0.001) in subjects on levothyroxine overall, and 1.83 points higher (0.93-2.73 P < 0.001) in individuals on levothyroxine who were also homozygous for Thr92Ala. Thr92Ala non-homozygous individuals on levothyroxine were 22% more likely than those not on levothyroxine to reach the threshold for HADS anxiety caseness, whilst homozygous individuals were 208% more likely. In GENTHYR individuals on higher doses of levothyroxine (≥100mg) with Thr92Ala had higher HADS caseness OR=1.86 (95%CI 1.10-3.14) P = 0.02, but this was not seen in individuals on lower doses.
Conclusion: Individuals homozygous for Thr92Ala in DIO2 on levothyroxine have significantly reduced quality of life compared to those non-homozygous, in a dose-dependent manner but there is no effect in the absence of LT4. Since individuals are not aware of their genotype, this provides strong objective evidence for a biological basis to persistence of symptoms in some individuals on LT4.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more